Anatomic Pathology Market
完整報告名稱與涵蓋範圍
Anatomic Pathology Market by Product [Consumables (Histopathology, Cytopathology), Instruments, Software], Process, Disease (Breast, GI, Prostate), End User (Hospitals, Research Labs), Services, Model (In House, Outsourced) – Global Forecast to 2031
報告摘要
The anatomic pathology market is projected to grow from USD 8.9 billion in 2026 to USD 14.5 billion by 2031, at a CAGR of 10.2%. The increasing global prevalence of cancer and other chronic diseases is driving demand for histopathology, cytopathology, and biomarker-based diagnostic testing. As healthcare systems increasingly adopt personalized medicine approaches, the need for accurate tissue characterization and biomarker assessment is expanding across a wide range of cancer types. Furthermore, advancements in digital pathology, artificial intelligence, laboratory automation, and multiplex tissue analysis technologies are improving diagnostic efficiency, workflow standardization, and clinical decision-making. These innovations are enabling healthcare providers to deliver more accurate and timely diagnoses, thereby supporting the growth of the anatomic pathology market.
“The breast cancer segment is expected to account for the largest share of the anatomic pathology market, by disease type.”
Based on disease type, the anatomic pathology market is segmented into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer (NSCLC), and other diseases. The breast cancer segment accounts for the largest market share due to the high global incidence of the disease and the extensive use of anatomic pathology techniques for disease diagnosis, classification, grading, and treatment planning. Pathology laboratories routinely utilize histopathology, immunohistochemistry (IHC), in situ hybridization (ISH), and biomarker assessment to support comprehensive evaluation of breast tissue specimens. Additionally, the increasing emphasis on early cancer detection, growing breast cancer screening initiatives, and rising demand for accurate pathological characterization continue to drive the adoption of anatomic pathology solutions, making breast cancer the largest disease segment within the market.
“The hospitals segment is expected to account for the largest share of the anatomic pathology market.”
The global anatomic pathology market can be segmented by end user into hospitals, research laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. Among these, the hospitals segment accounted for the largest market share. Hospitals remain the primary setting for anatomic pathology testing due to the high volume of cancer diagnoses, surgical procedures, and tissue-based examinations performed within integrated healthcare systems. Furthermore, the increasing availability of advanced pathology infrastructure, growing adoption of laboratory automation and digital pathology technologies, and rising demand for timely and accurate diagnostic services are expected to support the continued utilization of anatomic pathology solutions across hospital-based laboratories worldwide.
“The Asia Pacific is the fastest-growing market for anatomic pathology from 2026 to 2031.”
The global anatomic pathology market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region is witnessing a rapid increase in cancer incidence, creating significant demand for histopathology, cytopathology, and biomarker-based diagnostic services. China is expanding pathology laboratory capacity through healthcare infrastructure modernization initiatives and increasing investments in cancer diagnostics. India's growing network of tertiary-care hospitals, cancer centers, and private diagnostic laboratories is accelerating the adoption of advanced pathology technologies and laboratory automation. Meanwhile, Japan's aging population, high cancer screening rates, and increasing adoption of digital pathology solutions continue to support the expansion of the anatomic pathology market across the region.
The break-up of the profiles of primary participants in the anatomic pathology market:
• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (27%), Directors (18%), and Others (55%)
• By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (US), Koninklijke Philips N.V. (Netherlands), Merck KGaA (Germany), Bio SB (US), and Sakura Finetek Japan Co., Ltd. (Japan) are some of the key players in the anatomic pathology market.
Research Coverage:
This research report categorizes the anatomic pathology market into the product market by type (consumables, instruments, software, and storage systems), product market by process (preanalytics/sample preparation, advanced staining/IHC, primary & special staining, and digital pathology), product market by disease (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer, and other diseases), product market by end user (hospitals, research laboratories, pharmaceutical companies, contract research organizations, and other end users), service market by type (histopathology services and cytopathology services), service market by model (in-house and outsourced), service market by disease (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer, and other diseases, and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the anatomic pathology market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions; key strategies such as acquisitions, agreements, and product & service launches; and recent developments associated with the anatomic pathology market. Competitive analysis of upcoming startups in the anatomic pathology market ecosystem is covered in this report.
Reasons to buy this report:
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall anatomic pathology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (high incidence of cancer and other target diseases, growing demand for digital pathology, availability of reimbursement, and growing focus on personalized medicine), restraints (high cost of instruments and consumables), opportunities (expansion potential across emerging economies and increasing number of clinical trials for cancer therapeutics), and challenges (availability of refurbished products, stringent regulatory requirements, and shortage of skilled professionals) influencing the growth of the anatomic pathology market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the anatomic pathology market.
• Market Development: Comprehensive information about lucrative markets—the report analyzes the anatomic pathology market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the anatomic pathology market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US).
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.3 STUDY SCOPE 45
1.3.1 MARKETS COVERED & REGIONAL SCOPE 45
1.3.2 INCLUSIONS & EXCLUSIONS 46
1.3.3 YEARS CONSIDERED 47
1.4 CURRENCY CONSIDERED 47
1.5 STAKEHOLDERS 47
1.6 SUMMARY OF CHANGES 48
2 EXECUTIVE SUMMARY 49
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 49
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 50
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 51
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 52
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 53
3 PREMIUM INSIGHTS 54
3.1 ANATOMIC PATHOLOGY PRODUCT MARKET OVERVIEW 54
3.2 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE, 2026 VS. 2031 54
3.3 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2026 VS. 2031 55
3.4 ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE, 2026 VS. 2031 55
3.5 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2026 VS. 2031 56
3.6 ANATOMIC PATHOLOGY PRODUCT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
4 MARKET OVERVIEW 57
4.1 INTRODUCTION 57
4.2 MARKET DYNAMICS 57
4.2.1 DRIVERS 58
4.2.1.1 High incidence of cancer and other target diseases 58
4.2.1.2 Growing demand for digital pathology 59
4.2.1.3 Availability of reimbursement 60
4.2.1.4 Growing focus on personalized medicine 61
4.2.2 RESTRAINTS 62
4.2.2.1 High cost of instruments and consumables 62
4.2.3 OPPORTUNITIES 62
4.2.3.1 Expansion potential across emerging economies 62
4.2.3.2 Increasing number of clinical trials for cancer therapeutics 63
4.2.4 CHALLENGES 63
4.2.4.1 Availability of refurbished products 63
4.2.4.2 Stringent regulatory requirements 63
4.2.4.3 Shortage of skilled professionals 64
4.3 UNMET NEEDS & WHITE SPACES 64
4.3.1 UNMET NEEDS IN ANATOMIC PATHOLOGY MARKET 64
4.3.2 WHITE SPACE OPPORTUNITIES 65
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 66
4.4.1 INTERCONNECTED MARKETS 66
4.4.2 CROSS-SECTOR OPPORTUNITIES 67
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 68
4.5.1 KEY MOVES & STRATEGIC FOCUS 68
5 INDUSTRY TRENDS 69
5.1 PORTER’S FIVE FORCES ANALYSIS 69
5.1.1 BARGAINING POWER OF SUPPLIERS 70
5.1.2 BARGAINING POWER OF BUYERS 70
5.1.3 THREAT OF NEW ENTRANTS 70
5.1.4 THREAT OF SUBSTITUTES 70
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.2 MACROECONOMIC INDICATORS 71
5.2.1 INTRODUCTION 71
5.2.2 GDP TRENDS & FORECAST 71
5.3 SUPPLY CHAIN ANALYSIS 74
5.4 VALUE CHAIN ANALYSIS 75
5.5 ECOSYSTEM ANALYSIS 76
5.5.1 ANATOMIC PATHOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 77
5.6 PRICING ANALYSIS 77
5.6.1 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS,
BY KEY PLAYER, 2024–2026 78
5.6.2 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS,
BY REGION, 2024–2026 79
5.7 TRADE ANALYSIS 80
5.7.1 IMPORT SCENARIO (HS CODE 3822) 80
5.7.2 EXPORT SCENARIO (HS CODE 3822) 81
5.8 KEY CONFERENCES & EVENTS, 2026–2027 81
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82
5.10 INVESTMENT & FUNDING SCENARIO 83
5.11 CASE STUDY ANALYSIS 83
5.11.1 CASE STUDY 1: OPTIMIZING AUTOMATED TISSUE PROCESSING
EFFICIENCY TO REDUCE COST 83
5.11.2 CASE STUDY 2: OPERATIONAL EFFICIENCY IMPROVEMENTS THROUGH MILESTONE MEDICAL TISSUE PROCESSOR IMPLEMENTATION 84
5.11.3 CASE STUDY 3: WORKFLOW OPTIMIZATION THROUGH EXCELSIOR
AS TISSUE PROCESSOR 84
5.12 IMPACT OF 2025 US TARIFFS ON ANATOMIC PATHOLOGY MARKET 85
5.12.1 INTRODUCTION 85
5.12.2 KEY TARIFF RATES 85
5.12.3 PRICE IMPACT ANALYSIS 85
5.12.4 IMPACT ON REGION 86
5.12.4.1 North America 86
5.12.4.2 Europe 86
5.12.4.3 Asia Pacific 87
5.12.5 IMPACT ON END-USE INDUSTRIES 87
5.12.5.1 Hospitals 87
5.12.5.2 Research laboratories 87
5.12.5.3 Pharmaceutical companies 87
5.12.5.4 Contract research organizations (CROs) 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 KEY EMERGING TECHNOLOGIES 89
6.1.1 HISTOPATHOLOGY 89
6.1.2 CYTOPATHOLOGY 89
6.1.3 DIGITAL PATHOLOGY 89
6.2 COMPLEMENTARY TECHNOLOGIES 90
6.2.1 SPECIAL STAINING 90
6.3 ADJACENT TECHNOLOGIES 90
6.3.1 MASS SPECTROMETRY IMAGING (MSI) 90
6.4 TECHNOLOGY/PRODUCT ROADMAP 90
6.4.1 SHORT-TERM (2025–2027) | OPTIMIZATION & STANDARDIZATION
OF CORE REAGENTS 91
6.4.1.1 Core technology development 91
6.4.1.2 Product innovations 91
6.4.1.3 Market adoption 91
6.4.2 MID-TERM (2027–2030) | EXPANDED CAPABILITIES & SUSTAINABILITY 91
6.4.2.1 Advanced technology development 91
6.4.2.2 Product innovations 91
6.4.2.3 Market adoption 92
6.4.3 LONG-TERM (2030–2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT PRODUCTS 92
6.4.3.1 High-performance & integrated workflows 92
6.4.3.2 Product innovations 92
6.4.3.3 Market adoption 92
6.5 PATENT ANALYSIS 92
6.5.1 LIST OF MAJOR PATENTS 93
6.5.1.1 List of key patents 93
6.6 FUTURE APPLICATIONS 94
6.7 IMPACT OF AI/GENERATIVE AI ON ANATOMIC PATHOLOGY MARKET 95
6.7.1 INTRODUCTION 95
6.7.2 TOP USE CASES & MARKET POTENTIAL 95
6.7.3 KEY COMPANIES IMPLEMENTING AI 96
6.7.4 FUTURE OF AI 96
7 SUSTAINABILITY & REGULATORY LANDSCAPE 97
7.1 REGIONAL REGULATIONS & COMPLIANCE 97
7.1.1 REGULATORY ANALYSIS 97
7.1.1.1 North America 97
7.1.1.1.1 US 97
7.1.1.1.2 Canada 97
7.1.1.2 Europe 97
7.1.1.2.1 Germany 98
7.1.1.2.2 UK 98
7.1.1.2.3 France 99
7.1.1.3 Asia Pacific 99
7.1.1.3.1 China 99
7.1.1.3.2 Japan 99
7.1.1.3.3 India 100
7.1.1.4 Latin America 100
7.1.1.5 Middle East 100
7.1.1.5.1 Africa 101
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
7.2 SUSTAINABILITY INITIATIVES 103
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES
IN ANATOMIC PATHOLOGY MARKET 103
7.2.1.1 Eco-friendly initiatives 103
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 104
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 106
8.1 DECISION-MAKING PROCESS 106
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 106
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 106
8.2.2 BUYING CRITERIA 107
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 107
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109
8.5 MARKET PROFITABILITY 110
8.5.1 REVENUE POTENTIAL 110
8.5.2 COST DYNAMICS 110
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 111
9 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE 112
9.1 INTRODUCTION 113
9.2 CONSUMABLES 113
9.2.1 HISTOPATHOLOGY CONSUMABLES 114
9.2.1.1 Histopathology antibodies 116
9.2.1.1.1 Primary histopathology antibodies 118
9.2.1.1.1.1 Increasing adoption of precision medicine to drive market growth 118
9.2.1.1.2 Secondary histopathology antibodies 120
9.2.1.1.2.1 Growing focus on highly specific polymers to drive demand for histopathology secondary antibodies 120
9.2.1.2 Histopathology kits & reagents 122
9.2.1.2.1 Histopathology stains & solvents 124
9.2.1.2.1.1 Increasing adoption of advanced tissue staining techniques to drive growth of histopathology stains & solvents 124
9.2.1.2.2 Histopathology fixatives 125
9.2.1.2.2.1 Growing emphasis on tissue preservation and biomarker integrity to drive demand for histopathology fixation reagents 125
9.2.1.2.3 Other histopathology kits & reagents 127
9.2.1.3 Histopathology probes 129
9.2.1.3.1 Growing adoption of tissue-based pathology and precision diagnostics to drive demand for histopathology probes 129
9.2.1.4 Other histopathology consumables 131
9.2.2 CYTOPATHOLOGY CONSUMABLES 133
9.2.2.1 Cytopathology antibodies 135
9.2.2.1.1 Primary cytopathology antibodies 137
9.2.2.1.1.1 Advancements in biomarker research using cell analysis to support market growth 137
9.2.2.1.2 Secondary cytopathology antibodies 139
9.2.2.1.2.1 Expanding use of cytopathology for cancer screening to accelerate demand 139
9.2.2.2 Cytopathology kits & reagents 141
9.2.2.2.1 Cytopathology stains & solvents 143
9.2.2.2.1.1 Growing demand for cytology-based screening and cellular diagnostics to fuel cytopathology stains & solvents market 143
9.2.2.2.2 Cytopathology fixatives 144
9.2.2.2.2.1 Rising adoption of cytology-based screening and liquid-based cytology to support growth of cytopathology fixation reagents 144
9.2.2.2.3 Other cytopathology kits & reagents 146
9.2.2.3 Cytopathology probes 148
9.2.2.3.1 Increasing research to aid market growth 148
9.2.2.4 Other cytopathology consumables 150
9.3 INSTRUMENTS 151
9.3.1 SLIDE STAINING SYSTEMS 152
9.3.1.1 Availability of automated systems to drive market growth 152
9.3.2 TISSUE PROCESSING SYSTEMS 154
9.3.2.1 Rising adoption of automation to drive market growth 154
9.3.3 CELL PROCESSORS 157
9.3.3.1 Technological advancements in cytopathology testing to support growth of this market 157
9.3.4 MICROTOMES 158
9.3.4.1 Increasing demand for accurate tissue sectioning to support growth 158
9.3.5 EMBEDDING SYSTEMS 161
9.3.5.1 Advancements in tissue preparation technologies to support expansion of embedding systems market 161
9.3.6 COVERSLIPPERS 163
9.3.6.1 Increasing focus on laboratory automation and workflow efficiency to drive growth of coverslippers market 163
9.3.7 DIGITAL PATHOLOGY SCANNERS 164
9.3.7.1 Growing adoption of digital imaging to propel market 164
9.3.8 OTHER INSTRUMENTS 167
9.4 SOFTWARE 168
9.4.1 AI-INTEGRATED SOFTWARE 169
9.4.1.1 Growing adoption of artificial intelligence in pathology workflows to accelerate demand for AI-integrated software 169
9.4.2 NON-AI-INTEGRATED SOFTWARE 172
9.4.2.1 Increasing digitalization of pathology laboratories to drive demand for non-AI pathology software 172
9.5 STORAGE SYSTEMS 174
9.5.1 GROWING ADOPTION OF DIGITAL PATHOLOGY AND INCREASING DATA VOLUMES TO DRIVE DEMAND FOR PATHOLOGY STORAGE SYSTEMS 174
10 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS 176
10.1 INTRODUCTION 177
10.2 PREANALYTICS/SAMPLE PREPARATION 177
10.2.1 GROWING DEMAND FOR EFFICIENT SPECIMEN HANDLING AND LABORATORY AUTOMATION TO DRIVE GROWTH 177
10.3 ADVANCED STAINING/IHC 179
10.3.1 GROWING ADOPTION OF MULTIPLEX BIOMARKER ANALYSIS AND AUTOMATED STAINING WORKFLOWS TO SUPPORT MARKET GROWTH 179
10.4 PRIMARY & SPECIAL STAINING 181
10.4.1 GROWING DEMAND FOR SPECIALIZED TISSUE & CELLULAR CHARACTERIZATION TO DRIVE GROWTH 181
10.5 DIGITAL PATHOLOGY 183
10.5.1 GROWING ADOPTION OF WHOLE-SLIDE IMAGING AND AI-ENABLED WORKFLOWS TO DRIVE GROWTH OF DIGITAL PATHOLOGY 183
11 ANATOMIC PATHOLOGY MARKET, BY DISEASE 186
11.1 INTRODUCTION 187
11.2 BREAST CANCER 188
11.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO FUEL MARKET 188
11.3 NON-SMALL-CELL LUNG CANCER 190
11.3.1 RISING CASES OF LUNG CANCER TO DRIVE ADOPTION 190
11.4 PROSTATE CANCER 191
11.4.1 GROWING RATE OF PROSTATE CANCER TO PROPEL MARKET 191
11.5 GASTRIC CANCER 193
11.5.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST MARKET 193
11.6 LYMPHOMA 195
11.6.1 RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS
TO SUPPORT GROWTH 195
11.7 OTHER DISEASES 198
12 ANATOMIC PATHOLOGY MARKET VOLUME ANALYSIS,
BY DISEASE (NUMBER OF TESTS) 200
13 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER 201
13.1 INTRODUCTION 202
13.2 HOSPITALS 202
13.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH 202
13.3 RESEARCH LABORATORIES 204
13.3.1 RISING DEMAND FOR SPECIALTY TESTS TO DRIVE MARKET 204
13.4 PHARMACEUTICAL COMPANIES 206
13.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET 206
13.5 CONTRACT RESEARCH ORGANIZATIONS 208
13.5.1 GROWING DEMAND FOR OUTSOURCING ANALYTICAL TESTING & CLINICAL TRIAL SERVICES TO BOOST MARKET 208
13.6 OTHER END USERS 210
14 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE 213
14.1 INTRODUCTION 214
14.2 HISTOPATHOLOGY SERVICES 214
14.3 CYTOPATHOLOGY SERVICES 216
15 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE 218
15.1 INTRODUCTION 219
15.2 IN-HOUSE 219
15.3 OUTSOURCED 221
16 ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE 223
16.1 INTRODUCTION 224
16.2 BREAST CANCER 224
16.2.1 NON-SMALL CELL LUNG CANCER 226
16.2.2 PROSTATE CANCER 227
16.2.3 GASTRIC CANCER 229
16.2.4 LYMPOMA 230
16.2.5 OTHER DISEASE TYPE 232
17 ANATOMIC PATHOLOGY MARKET, BY REGION 234
17.1 INTRODUCTION 235
17.2 NORTH AMERICA 235
17.2.1 US 243
17.2.1.1 High healthcare expenditure to drive market 243
17.2.2 CANADA 250
17.2.2.1 Rising prevalence of cancer to fuel market 250
17.3 EUROPE 257
17.3.1 GERMANY 264
17.3.1.1 Favorable government initiatives to boost market 264
17.3.2 UK 271
17.3.2.1 Rising investments in cancer research to drive market 271
17.3.3 FRANCE 278
17.3.3.1 Increasing demand for cancer diagnostics to propel market 278
17.3.4 ITALY 285
17.3.4.1 High incidence of cancer and geriatric population to support growth 285
17.3.5 SPAIN 292
17.3.5.1 Increased cancer cases to boost market 292
17.3.6 REST OF EUROPE 299
17.4 ASIA PACIFIC 305
17.4.1 CHINA 313
17.4.1.1 Increasing focus on healthcare infrastructure to boost market 313
17.4.2 JAPAN 320
17.4.2.1 Established healthcare system to fuel market 320
17.4.3 INDIA 327
17.4.3.1 Presence of large patient pool and rapidly growing healthcare
sector to drive market 327
17.4.4 REST OF ASIA PACIFIC 334
17.5 LATIN AMERICA 341
17.5.1 GROWING ONCOLOGY PATIENT POOL, COMBINED WITH EXPANDING PUBLIC AND PRIVATE INVESTMENTS IN CANCER CARE, TO BOOST GROWTH 341
17.6 MIDDLE EAST & AFRICA 348
17.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO AID ANATOMIC PATHOLOGY MARKET 348
18 COMPETITIVE LANDSCAPE 356
18.1 INTRODUCTION 356
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 356
18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN ANATOMIC
PATHOLOGY MARKET 356
18.3 REVENUE ANALYSIS, 2023–2025 358
18.4 MARKET SHARE ANALYSIS, 2025 359
18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 359
18.4.2 US MARKET SHARE ANALYSIS, 2025 361
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 361
18.5.1 STARS 362
18.5.2 EMERGING LEADERS 362
18.5.3 PERVASIVE PLAYERS 362
18.5.4 PARTICIPANTS 362
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 364
18.5.5.1 Company footprint 364
18.5.5.2 Region footprint 364
18.5.5.3 Type footprint 365
18.5.5.4 Process footprint 365
18.5.5.5 End-user footprint 366
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 366
18.6.1 PROGRESSIVE COMPANIES 366
18.6.2 RESPONSIVE COMPANIES 366
18.6.3 DYNAMIC COMPANIES 367
18.6.4 STARTING BLOCKS 367
18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 368
18.6.5.1 Detailed list of key startups/SMEs 368
18.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 368
18.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 369
18.7 COMPANY VALUATION & FINANCIAL METRICS 369
18.7.1 FINANCIAL METRICS 369
18.7.2 COMPANY VALUATION 370
18.8 BRAND/PRODUCT COMPARISON 370
18.9 COMPETITIVE SCENARIO 371
18.9.1 PRODUCT LAUNCHES & APPROVALS 371
18.9.2 DEALS 372
18.9.3 EXPANSIONS 373
19 COMPANY PROFILES 374
19.1 KEY PLAYERS 374
19.1.1 F. HOFFMANN-LA ROCHE LTD. 374
19.1.1.1 Business overview 374
19.1.1.2 Products offered 375
19.1.1.3 Recent developments 377
19.1.1.3.1 Product launches & approvals 377
19.1.1.3.2 Deals 377
19.1.1.4 MnM view 378
19.1.1.4.1 Key strengths 378
19.1.1.4.2 Strategic choices 378
19.1.1.4.3 Weaknesses & competitive threats 378
19.1.2 DANAHER CORPORATION 379
19.1.2.1 Business overview 379
19.1.2.2 Products offered 380
19.1.2.3 Recent developments 382
19.1.2.3.1 Product launches & approvals 382
19.1.2.3.2 Deals 383
19.1.2.4 MnM view 384
19.1.2.4.1 Key strengths 384
19.1.2.4.2 Strategic choices 384
19.1.2.4.3 Weaknesses & competitive threats 384
19.1.3 PHC HOLDINGS CORPORATION (EPREDIA) 385
19.1.3.1 Business overview 385
19.1.3.2 Products offered 386
19.1.3.3 Recent developments 388
19.1.3.3.1 Product launches & approvals 388
19.1.3.3.2 Deals 388
19.1.3.4 MnM view 389
19.1.3.4.1 Key strengths 389
19.1.3.4.2 Strategic choices 389
19.1.3.4.3 Weaknesses & competitive threats 389
19.1.4 AGILENT TECHNOLOGIES, INC. 390
19.1.4.1 Business overview 390
19.1.4.2 Products offered 391
19.1.4.3 Recent developments 392
19.1.4.3.1 Product launches 392
19.1.4.3.2 Deals 393
19.1.4.4 MnM view 393
19.1.4.4.1 Key strengths 393
19.1.4.4.2 Strategic choices 393
19.1.4.4.3 Weaknesses & competitive threats 393
19.1.5 HOLOGIC INC. 394
19.1.5.1 Business overview 394
19.1.5.2 Products offered 395
19.1.5.3 Recent developments 396
19.1.5.3.1 Product approvals 396
19.1.5.4 MnM view 397
19.1.5.4.1 Key strengths 397
19.1.5.4.2 Strategic choices 397
19.1.5.4.3 Weaknesses & competitive threats 397
19.1.6 BECTON, DICKINSON AND COMPANY (BD) 398
19.1.6.1 Business overview 398
19.1.6.2 Products offered 399
19.1.6.3 Recent developments 401
19.1.6.3.1 Deals 401
19.1.6.3.2 Expansions 401
19.1.7 KONINKLIJKE PHILIPS N.V. 402
19.1.7.1 Business overview 402
19.1.7.2 Products offered 403
19.1.7.3 Recent developments 404
19.1.7.3.1 Deals 404
19.1.7.3.2 Expansions 405
19.1.8 MERCK KGAA 406
19.1.8.1 Business overview 406
19.1.8.2 Products offered 407
19.1.8.3 Recent developments 408
19.1.8.3.1 Expansions 408
19.1.9 SECTRA AB 409
19.1.9.1 Business overview 409
19.1.9.2 Products offered 410
19.1.9.3 Recent developments 411
19.1.9.3.1 Product approvals 411
19.1.9.3.2 Deals 411
19.1.9.3.3 Expansions 412
19.1.10 SAKURA FINETEK JAPAN CO., LTD. 413
19.1.10.1 Business overview 413
19.1.10.2 Products offered 413
19.1.10.3 Recent developments 415
19.1.10.3.1 Product launches 415
19.1.10.3.2 Deals 416
19.1.10.3.3 Expansions 416
19.2 OTHER PLAYERS 417
19.2.1 BIO SB 417
19.2.2 BIOGENEX 418
19.2.3 MILESTONE MEDICAL 419
19.2.4 HISTO-LINE LABORATORIES 420
19.2.5 DIAPATH S.P.A. 422
19.2.6 SLEE MEDICAL GMBH 423
19.2.7 AMOS SCIENTIFIC PTY LTD. 425
19.2.8 MEDITE MEDICAL GMBH 426
19.2.9 CELL SIGNALING TECHNOLOGY, INC. 427
19.2.10 CELLPATH LTD. 428
19.2.11 MICROS AUSTRIA 429
19.2.12 R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED 430
19.2.13 RWD LIFE SCIENCE CO., LTD. 431
19.2.14 MEDIMEAS 432
19.2.15 BRIGHT INSTRUMENTS 433
19.2.16 JINHUA YIDI MEDICAL APPLIANCE CO., LTD. 434
19.2.17 HAMAMATSU PHOTONICS K.K. 435
19.2.18 3DHISTECH LTD. 436
19.2.19 OPTRASCAN 437
19.2.20 DAKEWE 438
20 RESEARCH METHODOLOGY 439
20.1 RESEARCH DATA 439
20.1.1 SECONDARY DATA 440
20.1.1.1 List of secondary sources 440
20.1.1.2 Key data from secondary sources 441
20.1.2 PRIMARY DATA 441
20.1.2.1 Breakdown of primary interviews 443
20.2 MARKET SIZE ESTIMATION 444
20.2.1 TOTAL MARKET SIZE: ANATOMIC PATHOLOGY MARKET 444
20.2.2 BOTTOM-UP APPROACH 444
20.2.2.1 Approach 2: Study of annual reports and investor presentations 445
20.2.2.2 Approach 3: Primary interviews 445
20.2.2.3 Growth forecast 445
20.2.3 TOP-DOWN APPROACH 446
20.3 DATA TRIANGULATION 446
20.4 RESEARCH ASSUMPTIONS 447
20.4.1 STUDY-RELATED ASSUMPTIONS 447
20.5 STUDY ASSUMPTIONS 447
20.5.1 PARAMETRIC ASSUMPTIONS 448
20.5.2 GROWTH RATE ASSUMPTIONS 448
20.6 RESEARCH LIMITATIONS 449
20.7 RISK ASSESSMENT 449
21 APPENDIX 450
21.1 DISCUSSION GUIDE 450
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 454
21.3 CUSTOMIZATION OPTIONS 456
21.4 RELATED REPORTS 456
21.5 AUTHOR DETAILS 457
圖表清單 List of Tables & Figures
TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION,
2024 VS. 2030 VS. 2040 (MILLION) 58
TABLE 2 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS,
2024 VS. 2030 VS. 2040 (MILLION) 58
TABLE 3 % OF PERSONALIZED MEDICINES IN OVERALL DRUG APPROVAL
BY FDA, 2015–2024 61
TABLE 4 ANATOMIC PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 70
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 71
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS 72
TABLE 7 EUROPE: MACROECONOMIC INDICATORS 73
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS 73
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS 73
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 73
TABLE 11 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS,
BY KEY PLAYER, 2024–2026 (USD) 78
TABLE 12 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS,
BY REGION, 2024–2026 (USD) 79
TABLE 13 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 80
TABLE 14 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 81
TABLE 15 ANATOMIC PATHOLOGY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 81
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 85
TABLE 17 KEY PATENTS IN ANATOMIC PATHOLOGY MARKET, 2022–2026 93
TABLE 18 KEY COMPANIES IMPLEMENTING AI IN ANATOMIC PATHOLOGY MARKET 96
TABLE 19 CLASSIFICATION OF IVD DEVICES IN EUROPE 98
TABLE 20 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 99
TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 101
TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 101
TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 102
TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 102
TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 107
TABLE 27 KEY BUYING CRITERIA, BY END USER 107
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 108
TABLE 29 ANATOMIC PATHOLOGY MARKET: UNMET NEEDS IN VARIOUS
END-USE INDUSTRIES 109
TABLE 30 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE, 2024–2031 (USD MILLION) 113
TABLE 31 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 113
TABLE 32 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 114
TABLE 33 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 115
TABLE 34 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 35 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 36 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 37 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 116
TABLE 38 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 117
TABLE 39 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 40 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 41 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 42 PRIMARY HISTOPATHOLOGY ANTIBODIES AVAILABLE IN MARKET 118
TABLE 43 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 44 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 45 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 46 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 47 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 120
TABLE 48 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 49 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 50 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 51 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 122
TABLE 52 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 53 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 54 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 55 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 56 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY REGION, 2024–2031 (USD MILLION) 124
TABLE 57 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 58 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 59 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 60 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES,
BY REGION, 2024–2031 (USD MILLION) 126
TABLE 61 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 62 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 63 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 64 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY
KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 127
TABLE 65 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 66 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 67 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 68 HISTOPATHOLOGY PROBES AVAILABLE IN MARKET 129
TABLE 69 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES,
BY REGION, 2024–2031 (USD MILLION) 130
TABLE 70 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 71 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 72 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 73 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 74 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 75 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 76 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 77 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 133
TABLE 78 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 134
TABLE 79 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 80 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 81 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 82 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES,
BY TYPE, 2024–2031 (USD MILLION) 135
TABLE 83 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES,
BY REGION, 2024–2031 (USD MILLION) 136
TABLE 84 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 85 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 86 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 87 PRIMARY CYTOPATHOLOGY ANTIBODIES AVAILABLE IN MARKET 137
TABLE 88 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 138
TABLE 89 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 90 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 91 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 92 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 93 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 94 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 95 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 96 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 141
TABLE 97 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 98 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 99 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS
& REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 100 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 101 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 102 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 103 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 104 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 105 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES,
BY REGION, 2024–2031 (USD MILLION) 145
TABLE 106 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 107 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 108 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 109 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS
& REAGENTS, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 110 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 111 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 112 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 113 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 114 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 115 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 116 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 117 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 150
TABLE 118 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 119 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 120 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 121 ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE,
2024–2031 (USD MILLION) 152
TABLE 122 KEY SLIDE STAINING SYSTEMS AVAILABLE IN MARKET 152
TABLE 123 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE STAINING SYSTEMS,
BY REGION, 2024–2031 (USD MILLION) 153
TABLE 124 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE
STAINING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 125 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE STAINING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 126 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE STAINING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 127 KEY TISSUE PROCESSING SYSTEMS AVAILABLE IN MARKET 155
TABLE 128 ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 129 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 130 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 131 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 132 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 133 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 134 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 135 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 136 MICROTOMES AVAILABLE IN MARKET 159
TABLE 137 ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES, BY REGION,
2024–2031 (USD MILLION) 159
TABLE 138 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 139 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 140 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 141 ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 161
TABLE 142 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 143 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 144 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 145 ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS, BY REGION, 2024–2031 (USD MILLION) 163
TABLE 146 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS, BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 147 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 148 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 149 DIGITAL PATHOLOGY SCANNERS AVAILABLE IN MARKET 165
TABLE 150 ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY REGION, 2024–2031 (USD MILLION) 165
TABLE 151 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 152 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 153 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL
PATHOLOGY SCANNERS, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 154 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS,
BY REGION, 2024–2031 (USD MILLION) 167
TABLE 155 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 156 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 157 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 158 SOFTWARE AVAILABLE IN MARKET 169
TABLE 159 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE,
2024–2031 (USD MILLION) 169
TABLE 160 ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE,
BY REGION, 2024–2031 (USD MILLION) 170
TABLE 161 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 162 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 163 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 164 ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-AI-INTEGRATED SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 172
TABLE 165 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR
NON-AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 166 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 167 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR
NON-AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 168 ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS,
BY REGION, 2024–2031 (USD MILLION) 174
TABLE 169 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 170 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS,
BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 171 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 172 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 177
TABLE 173 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 174 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 175 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 176 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 177 ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC,
BY REGION, 2024–2031 (USD MILLION) 180
TABLE 178 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 179 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 180 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 181 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY & SPECIAL STAINING,
BY REGION, 2024–2031 (USD MILLION) 182
TABLE 182 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY
& SPECIAL STAINING, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 183 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY & SPECIAL STAINING, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 184 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY & SPECIAL STAINING, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 185 ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 186 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 187 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 188 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 189 GLOBAL CANCER INCIDENCE, 2022 VS. 2040 187
TABLE 190 ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 187
TABLE 191 BREAST CANCER INCIDENCE, BY REGION, 2024 VS. 2050 188
TABLE 192 ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 193 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 194 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 195 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 196 ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-SMALL-CELL LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 197 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR
NON-SMALL-CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 198 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-SMALL-CELL
LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 199 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-SMALL-CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 200 PROSTATE CANCER INCIDENCE, BY REGION, 2024 VS. 2050 192
TABLE 201 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 202 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 203 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 204 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 205 ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER, BY, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 206 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 207 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 208 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 195
TABLE 209 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2024 VS. 2050 196
TABLE 210 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2024 VS. 2050 196
TABLE 211 ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA,
BY REGION, 2024–2031 (USD MILLION) 196
TABLE 212 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 213 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 214 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 215 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 216 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 217 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 218 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 219 ANATOMIC PATHOLOGY MARKET, BY DISEASE, 2024–2031 (NO. OF TESTS) 200
TABLE 220 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 202
TABLE 221 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS, BY REGION,
2024–2031 (USD MILLION) 203
TABLE 222 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 223 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 224 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS,
BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 225 ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES,
BY REGION, 2024–2031 (USD MILLION) 205
TABLE 226 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 227 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 228 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 229 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 230 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 231 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 232 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 233 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 209
TABLE 234 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 235 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 236 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 237 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 211
TABLE 238 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER
END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 239 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 240 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 241 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 242 ANATOMIC PATHOLOGY SERVICE MARKET FOR HISTOPATHOLOGY SERVICES,
BY REGION, 2024–2031 (USD MILLION) 214
TABLE 243 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR HISTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 244 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR HISTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 245 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICES MARKET FOR HISTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 246 ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES,
BY REGION, 2024–2031 (USD MILLION) 216
TABLE 247 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 248 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 249 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 250 ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL, 2024–2031 (USD MILLION) 219
TABLE 251 ANATOMIC PATHOLOGY SERVICE MARKET FOR IN-HOUSE, BY REGION,
2024–2031 (USD MILLION) 219
TABLE 252 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR IN-HOUSE,
BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 253 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR IN-HOUSE,
BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 254 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR IN-HOUSE,
BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 255 ANATOMIC PATHOLOGY SERVICE MARKET FOR OUTSOURCED, BY REGION,
2024–2031 (USD MILLION) 221
TABLE 256 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR OUTSOURCED, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 257 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR OUTSOURCED,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 258 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR OUTSOURCED,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 259 ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 224
TABLE 260 ANATOMIC PATHOLOGY SERVICE MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 224
TABLE 261 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR BREAST
CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 262 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 263 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 264 ANATOMIC PATHOLOGY SERVICE MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 226
TABLE 265 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 266 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 267 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR NON-SMALL
CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 268 ANATOMIC PATHOLOGY SERVICE MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 269 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 270 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 271 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 272 ANATOMIC PATHOLOGY SERVICE MARKET FOR GASTRIC CANCER, BY, BY REGION, 2024–2031 (USD MILLION) 229
TABLE 273 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR GASTRIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 274 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR GASTRIC CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 275 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR GASTRIC CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 276 ANATOMIC PATHOLOGY SERVICE MARKET FOR LYMPHOMA, BY, BY REGION, 2024–2031 (USD MILLION) 230
TABLE 277 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR LYMPHOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 278 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR LYMPHOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 279 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR LYMPHOMA,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 280 ANATOMIC PATHOLOGY SERVICE MARKET FOR OTHER DISEASE TYPE, BY REGION, 2024–2031 (USD MILLION) 232
TABLE 281 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 282 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR OTHER DISEASE TYPE,
BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 283 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 284 ANATOMIC PATHOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 235
TABLE 285 NORTH AMERICA: ANATOMIC PATHOLOGY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 236
TABLE 286 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 237
TABLE 287 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 288 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 289 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 290 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 291 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 292 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 293 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 294 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 295 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE,
BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 296 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2024–2031 (USD MILLION) 241
TABLE 297 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 241
TABLE 298 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2024–2031 (USD MILLION) 242
TABLE 299 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 242
TABLE 300 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 242
TABLE 301 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 243
TABLE 302 US CANCER INCIDENCE, BY CANCER TYPE, 2024 VS. 2050 244
TABLE 303 US: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 244
TABLE 304 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 305 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 306 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 307 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS
& REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 308 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 309 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 310 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS
& REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 311 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 312 US: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE,
2024–2031 (USD MILLION) 247
TABLE 313 US: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 248
TABLE 314 US: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 248
TABLE 315 US: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 249
TABLE 316 US: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 249
TABLE 317 US: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 249
TABLE 318 US: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 250
TABLE 319 CANADA CANCER INCIDENCE, BY CANCER TYPE, 2024 VS. 2050 250
TABLE 320 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 321 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 322 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 323 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 324 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 325 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 326 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 327 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 328 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS,
BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 329 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE,
BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 330 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 255
TABLE 331 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 255
TABLE 332 CANADA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 256
TABLE 333 CANADA: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 334 CANADA: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 256
TABLE 335 CANADA: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 257
TABLE 336 EUROPE: ANATOMIC PATHOLOGY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 337 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 258
TABLE 338 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 339 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 340 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 341 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 342 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 343 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 344 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 345 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 346 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 347 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 262
TABLE 348 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 262
TABLE 349 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 263
TABLE 350 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 263
TABLE 351 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 263
TABLE 352 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 264
TABLE 353 GERMANY: CANCER INCIDENCE, BY TYPE, 2024 VS. 2050 264
TABLE 354 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 355 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 356 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 357 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 358 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 359 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 360 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 361 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 362 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS,
BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 363 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE,
BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 364 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 269
TABLE 365 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 269
TABLE 366 GERMANY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 270
TABLE 367 GERMANY: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 368 GERMANY: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 270
TABLE 369 GERMANY: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 271
TABLE 370 UK: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 272
TABLE 371 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 372 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 373 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 374 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 375 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 376 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 377 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 378 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 379 UK: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE,
2024–2031 (USD MILLION) 275
TABLE 380 UK: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 276
TABLE 381 UK: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 276
TABLE 382 UK: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 277
TABLE 383 UK: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 277
TABLE 384 UK: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 277
TABLE 385 UK: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 278
TABLE 386 FRANCE: CANCER INCIDENCE, BY TYPE, 2024 VS. 2050 278
TABLE 387 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 388 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 389 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 390 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 391 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 392 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 393 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 394 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 395 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 396 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 397 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 283
TABLE 398 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 283
TABLE 399 FRANCE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 284
TABLE 400 FRANCE: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 284
TABLE 401 FRANCE: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 284
TABLE 402 FRANCE: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 285
TABLE 403 ITALY: CANCER INCIDENCE, BY TYPE, 2024 VS. 2050 285
TABLE 404 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 286
TABLE 405 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 406 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 407 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 408 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 409 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 410 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 411 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 412 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 413 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 414 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 290
TABLE 415 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 290
TABLE 416 ITALY: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 291
TABLE 417 ITALY: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 418 ITALY: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 291
TABLE 419 ITALY: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 292
TABLE 420 SPAIN: CANCER INCIDENCE, BY TYPE, 2024 VS. 2050 292
TABLE 421 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 293
TABLE 422 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 423 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 424 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 425 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 426 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 427 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 428 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 429 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 430 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 431 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 297
TABLE 432 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 297
TABLE 433 SPAIN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 298
TABLE 434 SPAIN: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 298
TABLE 435 SPAIN: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 298
TABLE 436 SPAIN: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 299
TABLE 437 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 299
TABLE 438 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 439 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 440 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 441 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 442 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 443 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 444 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 445 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 446 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE,
BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 447 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2024–2031 (USD MILLION) 303
TABLE 448 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 303
TABLE 449 REST OF EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2024–2031 (USD MILLION) 304
TABLE 450 REST OF EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 451 REST OF EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 304
TABLE 452 REST OF EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 305
TABLE 453 ASIA PACIFIC: ANATOMIC PATHOLOGY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 306
TABLE 454 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 307
TABLE 455 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 456 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 457 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 458 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 459 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 460 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 309
TABLE 461 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 309
TABLE 462 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS,
BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 463 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE,
BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 464 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 311
TABLE 465 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 311
TABLE 466 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 312
TABLE 467 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 312
TABLE 468 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 312
TABLE 469 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 313
TABLE 470 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 314
TABLE 471 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 472 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 473 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 474 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 475 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 476 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 477 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 478 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 479 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 480 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 318
TABLE 481 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 318
TABLE 482 CHINA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 319
TABLE 483 CHINA: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 319
TABLE 484 CHINA: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 319
TABLE 485 CHINA: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 320
TABLE 486 CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2024 VS. 2050 320
TABLE 487 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 321
TABLE 488 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 489 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 490 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 322
TABLE 491 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 322
TABLE 492 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 322
TABLE 493 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 494 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 495 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 496 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 497 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 325
TABLE 498 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 325
TABLE 499 JAPAN: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 326
TABLE 500 JAPAN: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 326
TABLE 501 JAPAN: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 326
TABLE 502 JAPAN: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 327
TABLE 503 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 328
TABLE 504 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES,
BY TYPE, 2024–2031 (USD MILLION) 328
TABLE 505 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 328
TABLE 506 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 507 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 508 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 509 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 510 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY
KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 511 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 512 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 513 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 332
TABLE 514 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 332
TABLE 515 INDIA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 333
TABLE 516 INDIA: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 333
TABLE 517 INDIA: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 333
TABLE 518 INDIA: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 334
TABLE 519 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET,
BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 520 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 521 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 522 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 523 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 524 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 525 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 526 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 527 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 528 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 529 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2024–2031 (USD MILLION) 339
TABLE 530 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE, 2024–2031 (USD MILLION) 339
TABLE 531 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2024–2031 (USD MILLION) 340
TABLE 532 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 340
TABLE 533 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL, 2024–2031 (USD MILLION) 340
TABLE 534 REST OF ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE, 2024–2031 (USD MILLION) 341
TABLE 535 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE,
2024–2031 (USD MILLION) 342
TABLE 536 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 537 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 538 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 539 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 540 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 541 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 542 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 543 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 544 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE,
BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 545 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS,
2024–2031 (USD MILLION) 346
TABLE 546 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE,
2024–2031 (USD MILLION) 346
TABLE 547 LATIN AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER,
2024–2031 (USD MILLION) 347
TABLE 548 LATIN AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 347
TABLE 549 LATIN AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL,
2024–2031 (USD MILLION) 347
TABLE 550 LATIN AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE,
2024–2031 (USD MILLION) 348
TABLE 551 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET,
BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 552 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 553 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 554 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 555 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 556 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 557 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 558 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 559 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 352
TABLE 560 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 352
TABLE 561 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2024–2031 (USD MILLION) 353
TABLE 562 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE, 2024–2031 (USD MILLION) 353
TABLE 563 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2024–2031 (USD MILLION) 354
TABLE 564 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 354
TABLE 565 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL, 2024–2031 (USD MILLION) 354
TABLE 566 MIDDLE EAST & AFRICA: ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE, 2024–2031 (USD MILLION) 355
TABLE 567 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN ANATOMIC PATHOLOGY MARKET, JANUARY 2023–JULY 2026 356
TABLE 568 ANATOMIC PATHOLOGY MARKET: DEGREE OF COMPETITION 360
TABLE 569 ANATOMIC PATHOLOGY MARKET: REGION FOOTPRINT 364
TABLE 570 ANATOMIC PATHOLOGY MARKET: TYPE FOOTPRINT 365
TABLE 571 ANATOMIC PATHOLOGY MARKET: PROCESS FOOTPRINT 365
TABLE 572 ANATOMIC PATHOLOGY MARKET: END-USER FOOTPRINT 366
TABLE 573 ANATOMICAL PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 368
TABLE 574 ANATOMIC PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 368
TABLE 575 ANATOMIC PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF
STARTUPS/ SMES (2/2) 369
TABLE 576 ANATOMIC PATHOLOGY MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023– JULY 2026 371
TABLE 577 ANATOMIC PATHOLOGY MARKET: DEALS, JANUARY 2023–JULY 2026 372
TABLE 578 ANATOMIC PATHOLOGY MARKET: EXPANSIONS, JANUARY 2023– JULY 2026 373
TABLE 579 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 374
TABLE 580 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 375
TABLE 581 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JULY 2026 377
TABLE 582 F. HOFFMAN-LA ROCHE LTD.: DEALS, JANUARY 2023–JULY 2026 377
TABLE 583 DANAHER CORPORATION: COMPANY OVERVIEW 379
TABLE 584 DANAHER: PRODUCTS OFFERED 380
TABLE 585 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JULY 2026 382
TABLE 586 DANAHER CORPORATION: DEALS, JANUARY 2023–JULY 2026 383
TABLE 587 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW 385
TABLE 588 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED 386
TABLE 589 PHC HOLDINGS CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–OCTOBER 2025 388
TABLE 590 PHC HOLDINGS CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 388
TABLE 591 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 390
TABLE 592 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 391
TABLE 593 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 392
TABLE 594 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JULY 2026 393
TABLE 595 HOLOGIC INC.: COMPANY OVERVIEW 394
TABLE 596 HOLOGIC INC.: PRODUCTS OFFERED 395
TABLE 597 HOLOGIC, INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 396
TABLE 598 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 398
TABLE 599 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 399
TABLE 600 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023–JULY 2026 401
TABLE 601 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2023–JULY 2026 401
TABLE 602 KONINKLIJKE PHILIPS N.V: COMPANY OVERVIEW 402
TABLE 603 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 403
TABLE 604 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2023–JULY 2026 404
TABLE 605 KONINKLIJKE PHILIPS N.V.: EXPANSIONS, JANUARY 2023–JULY 2026 405
TABLE 606 MERCK KGAA: COMPANY OVERVIEW 406
TABLE 607 MERCK KGAA: PRODUCTS OFFERED 407
TABLE 608 MERCK KGAA: EXPANSIONS, JANUARY 2023–JULY 2026 408
TABLE 609 SECTRA AB: COMPANY OVERVIEW 409
TABLE 610 SECTRA AB: PRODUCTS OFFERED 410
TABLE 611 SECTRA AB: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 411
TABLE 612 SECTRA AB: DEALS, JANUARY 2023–JULY 2026 411
TABLE 613 SECTRA AB: EXPANSIONS, JANUARY 2023–JULY 2026 412
TABLE 614 SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW 413
TABLE 615 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS OFFERED 413
TABLE 616 SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES,
JANUARY 2023–JULY 2026 415
TABLE 617 SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2023–JULY 2026 416
TABLE 618 SAKURA FINETEK JAPAN CO., LTD.: EXPANSIONS, JANUARY 2023–JULY 2026 416
TABLE 619 BIO SB: COMPANY OVERVIEW 417
TABLE 620 BIOGENEX: COMPANY OVERVIEW 418
TABLE 621 MILESTONE MEDICAL: COMPANY OVERVIEW 419
TABLE 622 HISTO-LINE LABORATORIES: COMPANY OVERVIEW 420
TABLE 623 DIAPATH S.P.A.: COMPANY OVERVIEW 422
TABLE 624 SLEE MEDICAL GMBH: COMPANY OVERVIEW 423
TABLE 625 AMOS SCIENTIFIC PTY LTD.: COMPANY OVERVIEW 425
TABLE 626 MEDITE MEDICAL GMBH: COMPANY OVERVIEW 426
TABLE 627 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 427
TABLE 628 CELLPATH LTD.: COMPANY OVERVIEW 428
TABLE 629 MICROS AUSTRIA: COMPANY OVERVIEW 429
TABLE 630 R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED: COMPANY OVERVIEW 430
TABLE 631 RWD LIFE SCIENCE CO., LTD.: COMPANY OVERVIEW 431
TABLE 632 MEDIMEAS: COMPANY OVERVIEW 432
TABLE 633 BRIGHT INSTRUMENTS: COMPANY OVERVIEW 433
TABLE 634 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: COMPANY OVERVIEW 434
TABLE 635 HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW 435
TABLE 636 3DHISTECH LTD.: COMPANY OVERVIEW 436
TABLE 637 OPTRASCAN: COMPANY OVERVIEW 437
TABLE 638 DAKEWE: COMPANY OVERVIEW 438
TABLE 639 KEY DATA FROM PRIMARY SOURCES 442
TABLE 640 ANATOMIC PATHOLOGY MARKET: RISK ASSESSMENT 449
FIGURE 1 ANATOMIC PATHOLOGY MARKET SEGMENTATION & REGIONAL SCOPE 45
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 49
FIGURE 3 GLOBAL ANATOMIC PATHOLOGY MARKET, 2024–2031 49
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ANATOMIC
PATHOLOGY MARKET, 2023–2025 50
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF ANATOMIC PATHOLOGY MARKET 51
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN ANATOMIC
PATHOLOGY MARKET, 2025 52
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53
FIGURE 8 RISING CASES OF CANCER TO DRIVE MARKET GROWTH DURING
FORECAST PERIOD 54
FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 54
FIGURE 10 PREANALYTICS/SAMPLE PREPARATION SEGMENT TO LEAD MARKET
DURING FORECAST PERIOD 55
FIGURE 11 BREAST CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 55
FIGURE 12 HOSPITALS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 56
FIGURE 13 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 56
FIGURE 14 ANATOMIC PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 57
FIGURE 15 ANATOMIC PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 69
FIGURE 16 ANATOMIC PATHOLOGY MARKET: SUPPLY CHAIN ANALYSIS 74
FIGURE 17 ANATOMIC PATHOLOGY MARKET: VALUE CHAIN ANALYSIS 75
FIGURE 18 ANATOMIC PATHOLOGY MARKET: ECOSYSTEM ANALYSIS 76
FIGURE 19 ANATOMIC PATHOLOGY MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMERS’ BUSINESSES 82
FIGURE 20 NUMBER OF DEALS & FUNDING ACTIVITIES IN ANATOMIC PATHOLOGY MARKET 83
FIGURE 21 PATENT ANALYSIS FOR ANATOMIC PATHOLOGY, JANUARY 2016–DECEMBER 2025 93
FIGURE 22 MARKET POTENTIAL OF AI IN ANATOMIC PATHOLOGY MARKET 95
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 106
FIGURE 24 KEY BUYING CRITERIA, BY END USER 107
FIGURE 25 NORTH AMERICA: ANATOMIC PATHOLOGY MARKET SNAPSHOT 236
FIGURE 26 ASIA PACIFIC: ANATOMIC PATHOLOGY MARKET SNAPSHOT 306
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN ANATOMIC PATHOLOGY
MARKET, 2023–2025 (USD MILLION) 358
FIGURE 28 ANATOMIC PATHOLOGY MARKET SHARE ANALYSIS, 2025 (GLOBAL) 359
FIGURE 29 ANATOMIC PATHOLOGY MARKET SHARE ANALYSIS, 2025 (US) 361
FIGURE 30 ANATOMIC PATHOLOGY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 363
FIGURE 31 ANATOMIC PATHOLOGY MARKET: COMPANY FOOTPRINT 364
FIGURE 32 ANATOMIC PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 367
FIGURE 33 EV/EBITDA OF KEY VENDORS 369
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 370
FIGURE 35 ANATOMIC PATHOLOGY MARKET: BRAND/PRODUCT COMPARISON
FOR ANATOMIC PATHOLOGY 370
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 375
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 380
FIGURE 38 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025) 386
FIGURE 39 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 391
FIGURE 40 HOLOGIC INC.: COMPANY SNAPSHOT (2025) 395
FIGURE 41 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 399
FIGURE 42 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2025) 403
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 407
FIGURE 44 SECTRA AB: COMPANY SNAPSHOT (2025) 410
FIGURE 45 RESEARCH DESIGN 439
FIGURE 46 LIST OF PRIMARY SOURCES 442
FIGURE 47 KEY INDUSTRY INSIGHTS 443
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 443
FIGURE 49 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS 444
FIGURE 50 CAGR PROJECTIONS 445
FIGURE 51 TOP-DOWN APPROACH 446
FIGURE 52 DATA TRIANGULATION 447
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們